Investors may not be familiar with PRA Health Sciences (PRAH), but there’s a good chance that they’re familiar with one of dozens of drugs that PRA has helped make available to patients. The company is one of the world’s largest outsourcers of clinical trials, having worked with pharmaceutical companies on more than 100 drugs placed in the market since 2000.